Kevin Winthrop
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kevin Winthrop sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Kevin Winthrop: 5 sponsored US clinical trials, 2 recruiting.
Kevin Winthrop sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ototoxicity, Drug-Induced, with 1 trials.
Upper-quartile sponsor footprint
Kevin Winthrop sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
NCT07301320
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
NCT05730283
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
NCT03604406
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
NCT03672630
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
NCT03038178
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
Therapeutic Areas
What is open in the Kevin Winthrop pipeline
2 recruiting of 5 indexed (40% open); 2 completed (40%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Ototoxicity, Drug-Induced (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kevin Winthrop: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Kevin Winthrop sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Kevin Winthrop page
5 registered trials is a research-attention snapshot, not an endorsement of Kevin Winthrop or any single study.
- 2 of Kevin Winthrop's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ototoxicity, Drug-Induced is the condition Kevin Winthrop studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ototoxicity, Drug-Induced trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kevin Winthrop pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.